These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33797846)

  • 21. Low-dose CT for the spatial normalization of PET images: A validation procedure for amyloid-PET semi-quantification.
    Presotto L; Iaccarino L; Sala A; Vanoli EG; Muscio C; Nigri A; Bruzzone MG; Tagliavini F; Gianolli L; Perani D; Bettinardi V
    Neuroimage Clin; 2018; 20():153-160. PubMed ID: 30094164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical impact of amyloid PET using
    Matsuda H; Okita K; Motoi Y; Mizuno T; Ikeda M; Sanjo N; Murakami K; Kambe T; Takayama T; Yamada K; Suehiro T; Matsunaga K; Yokota T; Tateishi U; Shigemoto Y; Kimura Y; Chiba E; Kawashima T; Tomo Y; Tachimori H; Kimura Y; Sato N
    Ann Nucl Med; 2022 Dec; 36(12):1039-1049. PubMed ID: 36194355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
    Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
    JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET.
    Hsiao IT; Huang CC; Hsieh CJ; Wey SP; Kung MP; Yen TC; Lin KJ
    Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):908-20. PubMed ID: 23412134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies.
    Bourgeat P; Doré V; Doecke J; Ames D; Masters CL; Rowe CC; Fripp J; Villemagne VL;
    Neuroimage; 2021 Feb; 226():117593. PubMed ID: 33248259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative Brain Amyloid PET.
    Jagust WJ; Mattay VS; Krainak DM; Wang SJ; Weidner LD; Hofling AA; Koo H; Hsieh P; Kuo PH; Farrar G; Marzella L
    J Nucl Med; 2024 May; 65(5):670-678. PubMed ID: 38514082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
    Barthel H; Luthardt J; Becker G; Patt M; Hammerstein E; Hartwig K; Eggers B; Sattler B; Schildan A; Hesse S; Meyer PM; Wolf H; Zimmermann T; Reischl J; Rohde B; Gertz HJ; Reininger C; Sabri O
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1702-14. PubMed ID: 21547601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation of Structural MR Images from Amyloid PET: Application to MR-Less Quantification.
    Choi H; Lee DS;
    J Nucl Med; 2018 Jul; 59(7):1111-1117. PubMed ID: 29217736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of a New Imaging Technique Using the Glucose Metabolism to Amyloid Deposition Ratio in the Diagnosis of Alzheimer's Disease.
    Takahashi R; Ishii K; Yokoyama K; For The Alzheimer S Disease Neuroimaging Initiative EY
    Curr Alzheimer Res; 2017; 14(2):161-168. PubMed ID: 27334941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach.
    Royse SK; Minhas DS; Lopresti BJ; Murphy A; Ward T; Koeppe RA; Bullich S; DeSanti S; Jagust WJ; Landau SM;
    Alzheimers Res Ther; 2021 May; 13(1):99. PubMed ID: 33971965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies.
    Su Y; Flores S; Hornbeck RC; Speidel B; Vlassenko AG; Gordon BA; Koeppe RA; Klunk WE; Xiong C; Morris JC; Benzinger TLS
    Neuroimage Clin; 2018; 19():406-416. PubMed ID: 30035025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spatial Normalization of
    Lilja J; Leuzy A; Chiotis K; Savitcheva I; Sörensen J; Nordberg A
    J Nucl Med; 2019 Feb; 60(2):285-291. PubMed ID: 29903930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Centiloid scale analysis for
    Yamao T; Miwa K; Wagatsuma K; Shigemoto Y; Sato N; Akamatsu G; Ito H; Matsuda H
    Phys Med; 2021 Feb; 82():249-254. PubMed ID: 33677386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct influence of specific versus global connectivity on the different Alzheimer's disease biomarkers.
    Mutlu J; Landeau B; Gaubert M; de La Sayette V; Desgranges B; Chételat G
    Brain; 2017 Dec; 140(12):3317-3328. PubMed ID: 29194503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A universal neocortical mask for Centiloid quantification.
    Bourgeat P; Doré V; Rowe CC; Benzinger T; Tosun D; Goyal MS; LaMontagne P; Jin L; Weiner MW; Masters CL; Fripp J; Villemagne VL; ;
    Alzheimers Dement (Amst); 2023; 15(3):e12457. PubMed ID: 37492802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI.
    Akamatsu G; Ikari Y; Ohnishi A; Nishida H; Aita K; Sasaki M; Yamamoto Y; Sasaki M; Senda M
    Phys Med Biol; 2016 Aug; 61(15):5768-80. PubMed ID: 27405579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer's disease.
    Imabayashi E; Tamamura N; Yamaguchi Y; Kamitaka Y; Sakata M; Ishii K
    Ann Nucl Med; 2022 Oct; 36(10):865-875. PubMed ID: 35821311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.
    Ossenkoppele R; Rabinovici GD; Smith R; Cho H; Schöll M; Strandberg O; Palmqvist S; Mattsson N; Janelidze S; Santillo A; Ohlsson T; Jögi J; Tsai R; La Joie R; Kramer J; Boxer AL; Gorno-Tempini ML; Miller BL; Choi JY; Ryu YH; Lyoo CH; Hansson O
    JAMA; 2018 Sep; 320(11):1151-1162. PubMed ID: 30326496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.